About
Neurodegenerative therapies, BBB-crossing antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Team (20)
Clinical Trials (23)
View allTotal Trials
23
As Lead Sponsor
16
As Collaborator
7
Total Enrollment
1,917
By Phase
PHASE2: 2PHASE1: 12PHASE1/PHASE2: 3PHASE2/PHASE3: 3PHASE3: 1
By Status
COMPLETED: 14RECRUITING: 3ACTIVE_NOT_RECRUITING: 3TERMINATED: 2ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline23 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06602193Lead Sponsor
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
PHASE2Recruiting
50 participants
Started: Oct 24, 2024 · Completed: Feb 28, 2028
NCT06281158Lead Sponsor
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
PHASE1Completed
7 participants
Started: Mar 1, 2024 · Completed: Apr 30, 2024
NCT06181136Lead Sponsor
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
PHASE1/PHASE2Active, not recruiting
20 participants
Started: Dec 7, 2023 · Completed: Aug 31, 2028
NCT06075537Lead Sponsor
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
PHASE2/PHASE3Enrolling by invitation
99 participants
Started: Sep 20, 2023 · Completed: Jun 30, 2027
NCT05842941Collaborator
HEALEY ALS Platform Trial - Regimen G DNL343
PHASE2/PHASE3Completed
249 participants
Started: May 24, 2023 · Completed: Oct 29, 2024
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...